All articles
What Happens When You Stop Taking Mounjaro®? What to Expect
Reading time:
6 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
Can You Restart Taking Mounjaro® After Stopping?
If you’ve previously discontinued Mounjaro® for personal, financial, or other reasons—such as nausea or stomach upset during the initial weeks—you may have the option to restart the medication, but this should always be done under medical supervision. However, if your decision to stop was due to more serious issues, such as a diagnosis of pancreatitis or a severe allergic reaction while on the medication, your healthcare provider will likely advise against resuming Mounjaro®.
Should you and your provider determine that restarting Mounjaro® is appropriate, they can guide you through the re-initiation process, including any necessary dosage adjustments and ongoing monitoring to ensure your safety and effectiveness of the treatment.
How Mochi Health Helps Guide Your Weight Loss Journey
Mochi Health is dedicated to supporting your weight loss journey, whether you’re continuing or stopping Mounjaro®:
Personalized Monitoring: Regular consultations to assess your progress and make informed decisions regarding medication use.
Educational Support: Providing resources to help you manage your diet and lifestyle effectively.
Comprehensive Care: Ensuring any transitions in medication are smooth and supported by expert guidance.
If you’re interested to learn more about joining Mochi Health, see if you’re eligible to join Mochi Health today.
Key Takeaways
Discontinuing Mounjaro® is a decision that should be made with careful consideration and guidance from your healthcare provider. When discontinuing Mounjaro®, some individuals may experience weight regain, particularly if lifestyle changes are not maintained. It is important to develop a comprehensive plan that includes a balanced diet and regular physical activity that you enjoy in order to sustain the weight loss achieved during treatment.
By working with support systems like Mochi Health, you can achieve and maintain your weight loss and continue towards your health goals with confidence. Here at Mochi Health, we provide guidance tailored to your specific situation, ensuring that you remain informed about the best strategies to support your health and well-being, before, during, and even after Mounjaro®.
References:
Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D'Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight, 5(17), e140532. https://europepmc.org/article/pmc/pmc7526454
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Food and Drug Administrator. (n.d.-b). Mounjaro® (tirzepatide) injection, for subcutaneous use. Access Data FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
Karrar HR, Nouh MI, Nouh YI, Nouh MI, Khan Alhindi AS, Hemeq YH, Aljameeli AM, Aljuaid JA, Alzahrani SJ, Alsatami AA, Alkredees MA, Almuqati AO, Abanmi SN, Alshehri AM. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis. Cureus. 2023 Sep 27;15(9):e46091. https://www.cureus.com/articles/170540#!/
Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014 Oct;124(10):4223-6. doi: 10.1172/JCI78371. Epub 2014 Sep 9. PMID: 25202976; PMCID: PMC4191040. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191040/
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA, 327(6), 534–545. https://jamanetwork.com/journals/jama/fullarticle/2788781
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945. https://jamanetwork.com/journals/jama/fullarticle/2812936
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles















